SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies
for Alzheimer's disease is the focus of the most recent edition of
Neurotech Insights, the leading monthly industry newsletter covering drugs,
devices and diagnostics for the brain and nervous system.
This month's feature article reviews the competing hypotheses around
the cause of Alzheimer's disease including: the beta amyloid theory, tau
hypothesis, the APOE4 and vascular theory, anti-inflammatories, memory
enhancers, neuroprotection and mitochondrial boosters.
The issue also discusses leading therapies in development from the
following companies: Accera, Allon Therapeutics (TSX: NPC), Amgen, Avera,
Ceregene, CoMentis, Cortex, Cytos, Elan (NYSE: ELN), Eli Lilly, Epix,
Evotec (Nasdaq: EVTC), Gladstone Institute, Medivation (Nasdaq: MDVN),
Merck, Myriad Genetics, NsGene, Pfizer, Targacept (Nasdaq: TRGT), TauRx
Therapeutics, TorreyPines Therapeutics, Transtech Pharma, Transition
Therapeutics, Roche, Synosia and Wyeth.
In the monthly CEO interview series, Neurotech Insights checks in with
David Hung CEO of Medivation (Nasdaq: MDVN) to get an insider perspective
on how they are progressing in the development of Dimebon for Alzheimer's
and Huntington's. Also included in this issue is an in-depth analysis of
the highlights from the International Conference on Alzheimer's Disease
(ICAD) 2008 held recently in Chicago.
Each month Neurotech Insights provides in-depth feature articles, the
latest financing news, CNS product and clinical trial updates, executive
interviews, and public stock commentary based on a deep and intimate
knowledge of the commercial neuroscience industry, players and products.
Neurotech Insights subscribers also have access to a searchable web archive
with over 700 stories covering more than 500 companies, 260 investors, and
70 brain and nervous system indications.
Recent issues have covered a broad variety of markets: brain cancer,
cognitive impairment associated with schizophrenia, restless leg syndrome,
PTSD, autism, migraine, retinal disorders, CNS infections, and bipolar. To
order Neurotech Insights visit http://www.neurotechinsights.com
Neurotech Insights is published by NeuroInsights, the neurotech market
authority. NeuroInsights provides market reports, investment information,
industry events and strategic advisory services to venture funds, startups,
corporations, governments and financial institutions.
NeuroInsights created and maintains the NASDAQ(R) NeuroInsights(R)
Neurotech Index (Nasdaq: NERV), a pure play modified market-capitalization
weighted index designed to track the performance of the leading
neurotechnology companies which are listed and actively traded on one of
the three major U.S. stock exchanges.
Contact:
Casey Lynch,
Managing Director
NeuroInsights
clynch@neuroinsights.com
415-229-3225
http://www.neuroinsights.com
http://www.neurotechinsights.com
SOURCE NeuroInsights
 back to top
Related links:
http://www.neuroinsights.com
http://www.neurotechinsights.com
CONTACT:
Casey Lynch, Managing Director of
NeuroInsights, +1-415-229-3225, clynch@neuroinsights.com
|
